SOURCE: Cell Bio-Systems

October 19, 2005 13:36 ET

With Production Products in Hand, CBSI Receives Warm Reception at ASPS Convention

SAN DIEGO, CA -- (MARKET WIRE) -- October 19, 2005 -- Cell Bio-Systems, Inc.® (OTC: CBSI) announced today that last month's debut of the Tulip® Disposable product micro-cannula line was extremely successful. "The surgeons and their staffs are ready for disposable products, and the power of the Tulip Brand was very apparent," said Marc Pilkington, CEO. Four new products, part of a growing line of new instruments, were unveiled to over 2,000 surgeons at American Society of Plastic Surgery 2005 (ASPS), the nation's largest show focusing on education and products related to the plastic surgery industry.

Darin Andersen, President & COO, who also attended the ASPS show, stated that, "CBSI hit a major milestone here by moving beyond prototype and concept products to production instruments. Our production efforts are focused on completing our compliance with the FDA. We expect this phase to be complete by year end, paving the way for a major product sales launch in Q1 2006."

About Cell Bio-Systems, Inc.

Cell Bio-Systems, Inc. (CBSI) is a Nevada corporation whose operations are based in San Diego, California. Founded in 2004, Cell Bio-Systems is a Medical Device, Biotechnology Company seeking to manufacture and distribute patented technologies for the Plastic & Cosmetic Surgery, Biopsy, Orthopedic Surgery, Stem Cell Therapy and other Living Tissue markets. Cell Bio-System is the exclusive licensee of patented syringe connection devices which use the worldwide recognized Tulip brand name. Cell Bio-Systems will manufacture, market, and distribute medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets.

This press release contains certain forward-looking information about Cell Bio-Systems, Inc. ("Cell Bio-Systems") which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Cell Bio-Systems, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy, the grade and quantity of minerals in our projects may not be economic, we do not have fee title to our properties, but derive our right through leases and the Mining Law, we are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission, we trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Cell Bio-Systems does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:

    Investor Relations
    Bill Hales